Physicians Lack Incentives For FDA Postmarket Study Participation, But Progress ‘Adequate,’ GAO Finds
This article was originally published in The Gray Sheet
Participation in postmarket device studies can be low because physicians and patients lack incentives to sign up, but in general, progress on postapproval studies for class III products is “adequate.” But most postmarket surveillance studies, ordered under Section 522, are listed by FDA as inactive, a GAO report ordered by Rep. DeLauro finds.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.